The report on the Global Cancer Biomarkers Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of a comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is portioned into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Drivers
- Growing old age population
- Rising occurrences of cancer
- Advancement of technology
Restraints
Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography.
The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.
The report classifies the market into different segments based on type, biomolecule and application. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.
The report also covers the complete competitive landscape of the worldwide market with company profiles of key players such as:
- 9F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Affymetrix Inc
- Agilent Technologies
- Becton, Dickinson and Company
- Hologic, Inc.
- Illumina, Inc
- Merck & Co. Inc
- Qiagen N.V
- Sino Biological Inc.
- Thermo Fisher Scientific Inc.
A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.
SEGMENTATIONS IN THE REPORT:
By Type:
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Cervical cancer
- Liver cancer
- Lung cancer
- Others
By Biomolecule:
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
By Applications:
- Drug Discovery And Development
- Diagnostics
- Personalized Medicine
- Others
By Geography:
- North America (NA) – US, Canada & Rest of North America
- Europe (EU) – UK, Germany, France & Rest of Europe
- Asia Pacific (APAC) – China, Japan, India & Rest of APAC
- Latin America (LA) – Brazil & Rest of Latin America
- Middle East & Africa (MEA) – Middle East and Africa
The Global Cancer Biomarkers Market has been exhibited in detail in the following chapters -
Chapter 1 Cancer Biomarkers Market Preface
Chapter 2 Executive Summary
Chapter 3 Cancer Biomarkers Industry Analysis
Chapter 4 Cancer Biomarkers Market Value Chain Analysis
Chapter 5 Cancer Biomarkers Market Analysis By Type
Chapter 6 Cancer Biomarkers Market Analysis By Biomolecule
Chapter 7 Cancer Biomarkers Market Analysis By Applications
Chapter 8 Cancer Biomarkers Market Analysis By Geography
Chapter 9 Competitive Landscape Of Cancer Biomarkers Companies
Chapter 10 Company Profiles Of Cancer Biomarkers Industry
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.